-
公开(公告)号：US20050260745A1
公开(公告)日：2005-11-24
申请号：US11133092
申请日：2005-05-19
申请人： Karel Domansky , Linda Griffith , Steven Tannenbaum , Alan Wells
发明人： Karel Domansky , Linda Griffith , Steven Tannenbaum , Alan Wells
CPC分类号： B01L3/502715 , B01J2219/00315 , B01J2219/00743 , B01L3/50255 , B01L3/50273 , B01L3/502738 , B01L2300/0681 , B01L2300/0829 , B01L2300/0861 , B01L2400/0481 , B01L2400/0638 , B33Y80/00 , C12M23/12 , C12M23/40 , C12M25/14 , C12M29/10
摘要： A system has been constructed that recapitulate the features of a capillary bed through normal human tissue. The system facilitates perfusion of three-dimensional (3D) cell monocultures and heterotypic cell co-cultures at the length scale of the capillary bed. A major feature is that the system can be utilized within a “multiwell plate” format amenable to high-throughput assays compatible with the type of robotics commonly used in pharmaceutical development. The system provides a means to conduct assays for toxicology and metabolism and as a model for human diseases such as hepatic diseases, including hepatitis, exposure-related pathologies, and cancer. Cancer applications include primary liver cancer as well as metastases. The system can also be used as a means of testing gene therapy approaches for treating disease and inborn genetic defects.
摘要翻译： 已经构建了通过正常人体组织重现毛细血管床特征的系统。 该系统有助于在毛细血管床的长度尺度上灌注三维（3D）细胞单一培养物和异型细胞共培养物。 一个主要特征是该系统可以在“多孔板”格式中使用，适合与药物开发中通常使用的机器人类型相容的高通量测定。 该系统提供了进行毒理学和代谢测定的手段，并作为人类疾病（如肝脏疾病，包括肝炎，暴露相关病理和癌症）的模型。 癌症应用包括原发性肝癌以及转移瘤。 该系统还可用作测试基因治疗方法的手段，用于治疗疾病和先天性遗传缺陷。
-
公开(公告)号：US08318479B2
公开(公告)日：2012-11-27
申请号：US11133092
申请日：2005-05-19
CPC分类号： B01L3/502715 , B01J2219/00315 , B01J2219/00743 , B01L3/50255 , B01L3/50273 , B01L3/502738 , B01L2300/0681 , B01L2300/0829 , B01L2300/0861 , B01L2400/0481 , B01L2400/0638 , B33Y80/00 , C12M23/12 , C12M23/40 , C12M25/14 , C12M29/10
摘要： A system has been constructed that recapitulate the features of a capillary bed through normal human tissue. The system facilitates perfusion of three-dimensional (3D) cell monocultures and heterotypic cell co-cultures at the length scale of the capillary bed. A major feature is that the system can be utilized within a “multiwell plate” format amenable to high-throughput assays compatible with the type of robotics commonly used in pharmaceutical development. The system provides a means to conduct assays for toxicology and metabolism and as a model for human diseases such as hepatic diseases, including hepatitis, exposure-related pathologies, and cancer. Cancer applications include primary liver cancer as well as metastases. The system can also be used as a means of testing gene therapy approaches for treating disease and inborn genetic defects.
摘要翻译： 已经构建了通过正常人体组织重现毛细血管床特征的系统。 该系统有助于在毛细血管床的长度尺度上灌注三维（3D）细胞单一培养物和异型细胞共培养物。 主要特征是该系统可以在多孔板格式中使用，适合与药物开发中通常使用的机器人类型兼容的高通量测定。 该系统提供了进行毒理学和代谢测定的手段，并作为人类疾病（如肝脏疾病，包括肝炎，暴露相关病理和癌症）的模型。 癌症应用包括原发性肝癌以及转移瘤。 该系统还可用作测试基因治疗方法的手段，用于治疗疾病和先天性遗传缺陷。
-
3.发明授权Chemokine derived peptides that bind with chemokine receptor CXCR3 and uses for chronic wound and angiogenesis inhibition treatments 有权与趋化因子受体CXCR3结合并用于慢性伤口和血管发生抑制治疗的趋化因子衍生肽公开(公告)号：US08734775B2
公开(公告)日：2014-05-27
申请号：US13219375
申请日：2011-08-26
IPC分类号： A61K38/19 , A61K45/00 , C07K14/435
CPC分类号： A61K38/195 , A61K47/551 , C07K14/522
摘要： Disclosed are peptides having activity against receptor CXCR3 are disclosed that exhibit activity in preventing the formation of new vessels and activity in mediating the dissociation of newly-formed vessels and resolving of wounds in the later stages of wound healing. Preferred peptides are derived from the α-helix portion IP-10 (CXCL10) or from IP-9 (CXCL11), are nontoxic, and smaller than naturally occurring peptides, making them useful in therapies against diseases or disease states marked by unwanted angiogenesis, including tumorogenic diseases such as cancers, and in healing of chronic wounds.
摘要翻译： 公开了具有针对受体CXCR3的活性的肽，其表现出在预防新血管形成中的活性和介导新形成的血管解离和在伤口愈合后期分解伤口的活性。 衍生自α-螺旋部分IP-10（CXCL10）或来自IP-9（CXCL11）的优选肽是无毒的且小于天然存在的肽，使得它们可用于治疗由不想要的血管发生标记的疾病或疾病状态， 包括肿瘤发生疾病如癌症，以及慢性伤口愈合。
-
公开(公告)号：US20070014755A1
公开(公告)日：2007-01-18
申请号：US11479627
申请日：2006-07-01
申请人： Eric Beckman , Stephen Badylak , Alan Wells , Jianying Zhang , Donald Freytes
发明人： Eric Beckman , Stephen Badylak , Alan Wells , Jianying Zhang , Donald Freytes
CPC分类号： C08G18/3821 , A61K31/28 , A61K38/39 , A61K45/06 , A61K47/59 , A61K47/60 , A61L26/0019 , A61L26/0066 , A61L26/008 , A61L2300/104 , A61L2300/214 , A61L2300/252 , A61L2300/402 , A61L2300/404 , A61L2300/414 , A61L2300/418 , C08G18/10 , C08G18/3206 , C08G18/3218 , C08G18/4833 , C08G18/771 , C08G18/8022 , C08G2230/00
摘要： A composition includes at least one biologically active agent covalently attached to a first polymerizing molecule that is adapted to undergo a free radical polymerization. The first polymerizing molecule retains the ability to undergo free radical polymerization after attachment of the bioactive agent thereto. The first polymerizing molecule is preferably biocompatible. The polymerizing molecule can, for example. be dihydroxyphenyl-L-alanine (DOPA) or tyrosine. The composition can also include a second component synthesized by reacting at least one core molecule having a plurality of reactive hydrogen groups with at least one multi-isocyanate functional molecule to create a conjugate including terminal isocyanate groups. The conjugate molecule is reacted with a second polymerizing molecule that is adapted to undergo a free radical polymerization. The second polymerizing molecule includes a reactive hydrogen to react with the isocyanate groups of the conjugate. The second polymerizing molecule retains the ability to undergo the free radical polymerization after reaction with the conjugate. In several embodiments, the first polymerizing molecule and the second polymerizing molecule are the same and dihydroxyphenyl-L-alanine (DOPA) or tyrosine.
摘要翻译： 组合物包含共价连接到适于进行自由基聚合的第一聚合分子的至少一种生物活性剂。 第一聚合分子保留在生物活性剂附着后进行自由基聚合的能力。 第一聚合分子优选是生物相容的。 聚合分子可以，例如。 是二羟基苯基-L-丙氨酸（DOPA）或酪氨酸。 组合物还可以包括通过使具有多个反应性氢基团的至少一个核心分子与至少一个多异氰酸酯官能分子反应以产生包含末端异氰酸酯基团的缀合物而合成的第二组分。 共轭分子与适于进行自由基聚合的第二聚合分子反应。 第二聚合分子包括与偶联物的异氰酸酯基反应的反应性氢。 第二聚合分子保留在与缀合物反应后进行自由基聚合的能力。 在几个实施方案中，第一聚合分子和第二聚合分子是相同的，并且是二羟基苯基-L-丙氨酸（DOPA）或酪氨酸。
-
5.发明申请CHEMOKINE DERIVED PEPTIDES AND USES FOR CHRONIC WOUND AND ANGIOGENESIS INHIBITION TREATMENTS 有权化学发光肽和用于慢性创伤和血管生成抑制治疗的用途公开(公告)号：US20130053319A1
公开(公告)日：2013-02-28
申请号：US13219375
申请日：2011-08-26
CPC分类号： A61K38/195 , A61K47/551 , C07K14/522
摘要： Disclosed are peptides having activity against receptor CXCR3 are disclosed that exhibit activity in preventing the formation of new vessels and activity in mediating the dissociation of newly-formed vessels and resolving of wounds in the later stages of wound healing. Preferred peptides are derived from the α-helix portion IP-10 (CXCL10) or from IP-9 (CXCL11), are nontoxic, and smaller than naturally occurring peptides, making them useful in therapies against diseases or disease states marked by unwanted angiogenesis, including tumorogenic diseases such as cancers, and in healing of chronic wounds.
摘要翻译： 公开了具有针对受体CXCR3的活性的肽，其表现出在预防新血管形成中的活性和介导新形成的血管解离和在伤口愈合后期分解伤口的活性。 衍生自α-螺旋部分IP-10（CXCL10）或来自IP-9（CXCL11）的优选肽是无毒的且小于天然存在的肽，使得它们可用于治疗由不想要的血管发生标记的疾病或疾病状态， 包括肿瘤发生疾病如癌症，以及慢性伤口愈合。
-
公开(公告)号：US06235729B1
公开(公告)日：2001-05-22
申请号：US08824149
申请日：1997-03-25
申请人： Philip Chen , Timothy Turner , Alan Wells
发明人： Philip Chen , Timothy Turner , Alan Wells
IPC分类号： A61K3158
CPC分类号： A61K31/685 , A61K31/15 , A61K31/27 , A61K31/58
摘要： The present invention provides a method of inhibiting tumor progression in an individual in need of such treatment, comprising the step of administering to said individual a pharmacologically effective dose of a phospholipase C inhibitor. Also provided is a method of inhibiting metastasis in an individual in need of such treatment, comprising the step of administering to said individual a pharmacologically effective dose of a phospholipase C inhibitor. Further provided are pharmaceutical compositions, comprising a phospholipase C inhibitor of tumor invasiveness and metastasis and a pharmaceutically acceptable carrier and a pharmaceutical composition, comprising a phospholipase C inhibitor of tumor invasiveness and metastasis, a antineoplastic agent and a pharmaceutically acceptable carrier.
摘要翻译： 本发明提供抑制需要这种治疗的个体中肿瘤进展的方法，包括向所述个体施用药理学有效剂量的磷脂酶C抑制剂的步骤。 还提供了在需要这种治疗的个体中抑制转移的方法，包括向所述个体施用药理学有效剂量的磷脂酶C抑制剂的步骤。 还提供了包含肿瘤侵袭和转移的磷脂酶C抑制剂和药学上可接受的载体和药物组合物的药物组合物，其包含肿瘤侵袭和转移的磷脂酶C抑制剂，抗肿瘤剂和药学上可接受的载体。
-
公开(公告)号：US5120332A
公开(公告)日：1992-06-09
申请号：US435122
申请日：1989-11-13
申请人： Alan Wells
发明人： Alan Wells
CPC分类号： F23C15/00 , B01D53/0423 , B01D53/047 , F02G1/0435 , F02G3/00 , F25B9/145 , B01D2253/102 , B01D2253/108 , B01D2256/12 , B01D2257/102 , B01D2257/104 , B01D2259/65 , F02G2243/52
摘要： A gas resonance device (101) comprises a pulsed combustor (102) located in the middle of a substantially spherical resonance chamber (103). Such a thermally driven gas resonance device has the advantage that the wall friction losses are eliminated altogether. A thermally driven gas resonance device (1, 101) may be combined with a pressure swing gas separator (16, 108), the oscillating gas in the gas resonance device (1, 101) being used to provide the pressure changes required to drive the pressure swing gas separator. Alternatively a thermally driven gas resonance device (1, 101) is combined with a heat pump (19, 120) with the oscillating gas in the gas resonance device (1, 101) being used to provide the power to operate the heat pump. The thermally driven gas resonance device (1, 101) may also drive an electrical generator (121, 122) to provide a combined heat and power device.
摘要翻译： 气体共振装置（101）包括位于大致球形共振室（103）中间的脉冲燃烧室（102）。 这种热驱动气体共振装置具有完全消除壁摩擦损失的优点。 热驱动气体共振装置（1,101）可以与变压气体分离器（16,108）组合，气体共振装置（1,101）中的振荡气体用于提供驱动气体共振装置 变压气体分离器。 或者，热驱动气体共振装置（1,101）与热泵（19,120）组合，气体共振装置（1,101）中的振荡气体用于提供操作热泵的功率。 热驱动气体共振装置（1,101）还可以驱动发电机（121,122）以提供组合的热和功率装置。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.024 秒)
